As part of the Inflation Reduction Act, price negotiations with manufacturers will begin this year, with reduced prices ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk ...

Jason Foster, CEO of Ori Biotech, discusses the difficulties preventing more widespread adoption of these advanced therapies.

Organizations including Gilead, Eli Lilly, and AbbVie announced a number of deals addressing inflammatory diseases, multiple myeloma, and other disease areas. With the start of the annual JP Morgan ...

Casey McPherson, Founder and CEO of Chrysalis Genetics, talks about his daughter's rare genetic condition, and how it led him to antisense oligonucleotides (ASOs) and therapeutic development for rare ...

Novo Holdings announced an investment in a $200M Series A launch financing for Swiss company Windward Bio. 1 The clinical stage drug development company is developing treatments for immunological ...

Johnson & Johnson (J&J) announced that it has acquired Intra-Cellular Therapies, a biopharmaceutical company. According to the company, the acquisition includes Caplyta (lumateperone), a once-daily ...

Under terms of the deal, GSK will also acquire IDRX-42, a tyrosine kinase inhibitor designed to treat both primary and secondary KIT mutations in patients with gastrointestinal stromal tumors. GSK ...

Pharmaceutical companies’ direct-to-patient (DTP) programs have recently sparked conversations and criticism in fear of their ...

Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...

A new offering in collaboration with Progyny, Inc makes fertility/family-building services more accessible and equitable.